Navigation Links
Arena Pharmaceuticals to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference
Date:10/7/2008

SAN DIEGO, Oct. 7 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the Natixis Bleichroeder Second Annual Hidden Gems Conference on October 13, 2008 at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time) at the Waldorf=Astoria Hotel in New York City. Robert E. Hoffman, Arena's Vice President, Finance and Chief Financial Officer, is scheduled to provide an overview of the company, including its clinical development and discovery programs.

A live audio webcast of the presentation will be available under the investor relations section of Arena's website at http://www.arenapharm.com. A replay of the presentation will be available for 30 days following the event. Please connect to Arena's website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for the treatment of obesity. Arena's broad pipeline of novel compounds target G protein-coupled receptors, an important class of validated drug targets, and includes compounds being evaluated independently and with partners, including Merck & Co., Inc. and Ortho-McNeil Pharmaceutical, Inc.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceutic
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
3. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
4. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
5. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Arena Pharmaceuticals to Report Third Quarter 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, October 17, 2007
7. Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results
8. Arena Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors
10. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
11. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Canada (PRWEB) July 10, 2014 ... present in very low abundance and are often ... challenging and time-consuming. , Join presenters Dr. Rowel ... and Dr. John Anders, Head of Quality at ... spectrometer-based approach that can speed detection and quantitation ...
(Date:7/10/2014)... Poway, CA (PRWEB) July 10, 2014 Robert ... Regenerative Veterinary Medicine company, is proud to announce the relaunch ... Pets, launching with a new series called “ What are ... to give an honest and straightforward foundation in the basics ... an educated decision on the right type of treatment when ...
(Date:7/10/2014)... On July 9 Prime Minister ... Russia,s first national "Industry" award ... is developing a unique project called MabNext . ... number of innovative drugs based on monoclonal antibodies for ... place at the International Exhibition "Innoprom 2014" in Ekaterinburg. ...
(Date:7/10/2014)... -- According to the International Atomic Energy Agency ... from terrorists acquiring sufficient quantities of plutonium or ... nuclear explosive device. The IAEA also notes that ... gram-level quantities, which can be challenging to detect ... new study appearing this week in the ...
Breaking Biology Technology:Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2Sensitive detection method may help impede illicit nuclear trafficking 2
... , MOUNTAIN VIEW, Calif., Aug. 26 ... a special meeting of stockholders held today, its stockholders approved the ... to purchase shares of the Company,s common stock to Symphony Capital ... completed its acquisition of Symphony Allegro, and as a result, Alexza ...
... , , , ... ) and Terrabon, L.L.C., today announced an agreement by Waste Management ... is the leading provider of comprehensive waste management and environmental services ... Management joins Valero Energy Corporation (NYSE: VLO ), the ...
... a valuable source of biofuel. Researchers writing in BioMed ... have shown that the juice of reject watermelons can ... with a team of researchers at the USDA-Agricultural Research ... US, to evaluate the biofuel potential of juice from ...
Cached Biology Technology:Alexza Stockholders Approve Share Issuance to Symphony Capital and Alexza Completes Acquisition of Symphony Allegro 2Alexza Stockholders Approve Share Issuance to Symphony Capital and Alexza Completes Acquisition of Symphony Allegro 3Alexza Stockholders Approve Share Issuance to Symphony Capital and Alexza Completes Acquisition of Symphony Allegro 4Waste Management and Terrabon Announce Investment Agreement for Waste-To-Fuel Conversion Technology 2Waste Management and Terrabon Announce Investment Agreement for Waste-To-Fuel Conversion Technology 3Waste Management and Terrabon Announce Investment Agreement for Waste-To-Fuel Conversion Technology 4
(Date:7/10/2014)... Amyloid diseases, such as Alzheimer,s disease, type ... share the common trait that proteins aggregate into ... vitro studies have found that neither the amylin ... toxic. New evidence using two-dimensional infrared (2D IR) ... amylin aggregation pathway that may explain toxicity, opening ...
(Date:7/10/2014)... Geostationary Operational Environmental Satellite or GOES-West satellite spotted ... fires raging in Canada,s Northwestern Territories. , At ... 2014, GOES-West captured this image of the brownish-colored ... Territories that drifted all the way into South ... GOES Project at NASA Goddard Space Flight Center, ...
(Date:7/10/2014)... MDBrightFocus Foundation, a nonprofit organization funding cutting-edge, innovative ... of glaucoma and macular degeneration, today announced the ... 55 scientists in 19 U.S. states, the District ... http://www.brightfocus.org/Grants2014 . , With these latest grants, ... in research funding in 2014. , The research ...
Breaking Biology News(10 mins):New technology reveals insights into mechanisms underlying amyloid diseases 2BrightFocus Foundation announces 55 new grantees in Alzheimer's and vision research 2BrightFocus Foundation announces 55 new grantees in Alzheimer's and vision research 3
... in the brain that help make HIV disease incurable, scientists ... biological vacuum cleaner that prevents anti-HIV drugs from reaching the ... HIV. They describe the advance, which allows medications to cross ... the Journal of the American Chemical Society . ...
... 12 October 2011, Singapore A new biotech ... of Singapore (NUS), to provide research tools, targeting the ... has been founded by two NUS faculty members: Dr ... Dr Kevin Tan from the NUS Department of Microbiology. ...
... carbon dioxide than it can bind. Local variations have increased the ... a study of how carbon dioxide flows between the water of ... the University of Gothenburg, Sweden. "The capacity of the ... acidity of the water has changed in recent centuries. In the ...
Cached Biology News:Launch of BioLynx provides a boost for the international malaria research community 2The Baltic Sea contributes carbon dioxide to the atmosphere 2
casein kinase 2, alpha 1 polypeptide, transcript variant 2, mRNA (cDNA clone MGC:15232 IMAGE:4121882), complete cds...
...
UV LAMP 300 NM 8W T5, 1 EA. Category: Nucleid Acid Detection Systems....
MOUSE ANTI S. MUTANS PEPTIDOGLYCAN...
Biology Products: